Pfizer Reaches $94M Settlement Over Celebrex Claims
Pfizer and a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have told a Virginia federal court that they have reached...To view the full article, register now.
Already a subscriber? Click here to view full article